LGALS1 and renal carcinoma: The anti-proliferative properties of OTX008 were previously demonstrated in many cancer cell lines, including colon (HT29, COLO205-S, HCC2998, HCT116, COLO205-R), ovarian (A2780-1A9, OVCAR 3, IGROV1, SKOV3), prostate (PC3, DU 145), head and neck (SQ20B, SCC91, HEP2), breast (MCFS7, SK BR3, ZR-75-1, MCF7-shWISP), and renal cancer lines (CAKI 1), with IC50 values ranging from 3 to 500 μM, demonstrating the variable response which can be obtained with such a Gal-1 inhibitor [11].